苏州大学附属苏州九院;
本研究通过纳入苏州大学附属苏州九院2021年3月-2024年3月期间收治的133例IgA肾病（Immunoglobulin A nephropathy,IgAN）患者的临床资料进行回顾性分析，其中合并乙型肝炎病毒（Hepatitis B virus,HBV）感染39例作为感染组，94例未感染者作为未感染组。另选取无肾脏疾病的单纯乙型肝炎病毒感染病患80例作为对照组。并采用实时荧光定量PCR技术检查感染组血清HBV-DNA载量，根据载量的不同将其分为高载量组（n=19）、中载量组（n=12）和低载量组（n=8），比较各组患者血清sCD89、C1GalT1水平差异，并通过spearman相关性分析法分析上述血清指标与HBV-DNA载量的相关性，应用受试者工作曲线分析其对IgAN伴HBV感染的诊断价值。结果显示，感染组血清sCD89水平高于未感染组和对照组，C1GalT1较对照组和未感染组偏低，且随着感染组患者HBVDNA载量的升高，血清sCD89呈升高趋势，血清C1GalT1呈降低趋势（均P<0.05）。血清sCD89、C1GalT1水平单独检测诊断IgA肾病HBV感染的AUC分别为0.737(0.623～0.871)、0.755(0.634～0.881)，两项指标联合检测后，其AUC提高至0.916(0.815～0.923)。相关性分析结果显示，血清sCD89水平与IgA肾病伴HBV感染患者HBVDNA载量呈正相关（r=0.604,P<0.05）；血清C1GalT1与HBV-DNA载量呈负相关（r=-0.711,P<0.05）。提示血清sCD89和C1GalT1水平变化与IgA肾病伴乙型肝炎病毒感染及HBV-DNA载量的增加相关，且两者联合检测具有更高的诊断效能。
| 105 | 0 | 101 |
| 下载次数 | 被引频次 | 阅读次数 |
[2] Girndt M.[Immunglobulin-A-Nephropathie–neue therapeutische M?glichkeiten][J]. Inn Med(Heidelb),2024, 65(4):407-413. DOI:10. 1007/s00108-024-01665-8.
[3] Wang K, Yu Z, Huang Y, et al. Clinicopathological features, risk factors, and outcomes of immunoglobulin A nephropathy associated with hepatitis B virus infection[J]. J Nephrol, 2021, 34(6):1887-1896. DOI:10. 1007/s40620-021-01004-2.
[4] Gao MZ, Xu LL, Li Y, et al. Hepatitis B virus status and clinical outcomes in IgA nephropathy[J]. Kidney Int Rep, 2024, 9(4):1057-1066. DOI:10. 1016/j.ekir. 2024. 01. 009.
[5]夏敏，吴复泉，应光辉，等. IgA肾病与乙型肝炎病毒感染的相关分析[J].中华医院感染学杂志，2018, 28(1):14-17. DOI:10. 11816/cn. ni. 2018-171392.
[6] Wu H, Wang X, Yang Z, et al. Serum soluble CD89-IgA complexes are elevated in IgA nephropathy without immunosuppressant history[J]. Dis Markers, 2020,2020:8393075. DOI:10. 1155/2020/8393075.
[7]王思瑜.通利三焦、清热利湿方对IgA肾病大鼠肾组织TGF-β1、C1GalT1及其分子伴侣Cosmc的影响[D].河北中医学院，2020. DOI:10. 27982/d. cnki.ghbyz. 2020. 000169.
[8]陈慧，徐俊驰，朱月萍，等. HIV合并肝炎病毒感染肝功能相关指标及免疫功能变化分析[J].标记免疫分析与临床，2023, 30(8):1310-1315. DOI:10. 11748/bjmy. issn. 1006-1703. 2023. 08. 009.
[9]张宏. KDIGO指南解读：IgA肾病治疗[J].中国实用内科杂志，2012, 32(12):925-927.
[10]Ogunnaike M, Das S, Raut SS, et al. Chronic hepatitis B infection:new approaches towards cure[J].Biomolecules, 2023, 13(8):1208. DOI:10. 3390/biom13081208.
[11]Bai Q, Li R, He X, et al. Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma[J]. Front Immunol, 2023, 14:1320414.DOI:10. 3389/fimmu. 2023. 1320414.
[12]De Crignis E, Hossain T, Romal S, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma[J]. ELife, 2021, 10:e60747. DOI:10. 7554/elife. 60747.
[13]Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy[J]. J Health Econ Outcomes Res, 2021, 8(2):36-45. DOI:10. 36469/001c. 26129.
[14]Wan Y, Yu LG. Expression and impact of C1GalT1 in cancer development and progression[J]. Cancers(Basel), 2021, 13(24):6305. DOI:10. 3390/cancers13246305.
[15]Walker A, Schwarz T, Brinkmann-Paulukat J, et al.Immune escape pathways from the HBV core 18-27CD8 T cell response are driven by individual HLA class I alleles[J]. Front Immunol, 2022, 13:1045498.DOI:10. 3389/fimmu. 2022. 1045498.
[16]Tian H, Yu JL, Chu X, et al. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression[J]. Front Oncol, 2024, 14:1389713. DOI:10. 3389/fonc. 2024. 1389713.
[17]Di Leo V, Gleeson PJ, Sallustio F, et al. Rifaximin as a potential treatment for IgA nephropathy in a humanized mice model[J]. J Pers Med, 2021, 11(4):309. DOI:10. 3390/jpm11040309.
[18]Abbad L, Monteiro RC, Berthelot L. Food antigens and transglutaminase 2 in IgA nephropathy:molecular links between gut and kidney[J]. Mol Immunol, 2020,121:1-6. DOI:10. 1016/j. molimm. 2020. 02. 019.
[19]冯泓源，朱斌.可溶性CD89参与IgA肾病发病机制的研究进展[J].中国中西医结合肾病杂志，2024, 25(3):277-279. DOI:10. 3969/j. issn. 1009-587X. 2024. 03. 031.
[20]Cambier A, Dossier C, Hogan J, et al. Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case[J].Pediatr Nephrol, 2022, 37(7):1597-1603. DOI:10. 1007/s00467-021-05381-5.
[21]Xing Y, Li L, Zhang Y, et al. C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy[J]. BMC Nephrol, 2020, 21(1):18. DOI:10. 1186/s12882-019-1675-5.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004617
中图分类号:R692.6
引用信息:
[1]刘蔚,华斐,凌凯等.血清sCD89、C1GalT1变化与HBV感染IgA肾病以及HBV-DNA载量的相关性研究[J].病毒学报,2024,40(06):1391-1396.DOI:10.13242/j.cnki.bingduxuebao.004617.
基金信息: